ClinicalTrials.gg
TerminatedNCT00379366RASTAUpdated Mar 18, 2015

External Ionizing Radiation to Prevent Restenosis on Haemodialysis Vascular Access

A Phase 2/3 interventional study of External ionizing radiations in Renal Insufficiency, Chronic, Graft Occlusion, Vascular and Thrombosis, sponsored by University Hospital, Bordeaux. Terminated at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-18.

Sponsored by University Hospital, Bordeaux · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
lack of patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 238 studies in Renal Insufficiency, Chronic with a site in France — 55 open to participants now, 69 under way, 17 of them phase 3. Renal Insufficiency, Chronic · France.

Enrollment
160th of 165
5 · median 170
Started
2006
with 4 others
Phase 2/3
Only one
of the 238
Registered
7th of 238
by date

Among the 238 studies in Renal Insufficiency, Chronic with a site in France, this one is the 160th largest by enrollment of the 165 interventional ones that give a count, is one of 5 that started in 2006, is the only one in phase 2/3, and was the 7th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

55 of the 238 studies in Renal Insufficiency, Chronic with a site in France are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 238 studies in Renal Insufficiency, Chronic with a site in France, or all of them as a file.
02

Study summary

Although ionizing radiations have been proposed for the prevention of intimal hyperplasia in coronary and peripheral arteries, information is lacking on how irradiation may prevent neointimal smooth-muscle cell proliferation and restenosis on prosthetic haemodialysis vascular access. We will assess the preventive effect of one dose of radiations (14 Gy) administered transcutaneously one day after dilatation of stenosis on prosthetic haemodialysis vascular access in a randomized controlled trial with a standardized clinical and ultrasonographic one-year follow-up.

Read the detailed description

Background: one of the major clinical concerns of prosthetic haemodialysis access is the risk of possible restenosis after stenosis dilatation. Only 25% of dilated prosthetic haemodialysis vascular accesses remain patent at one year. No available pharmacological agents can yet effectively prevent it. After stenosis dilatation the vascular wall responds to mechanical injury in a standardized manner: intimal smooth-muscle cells migrate and proliferate, a neointima gradually begins to form and the cell phenotype changes from contractile to secretory. One way to inhibit the neointimal proliferation responsible for restenosis is to induce cell apoptosis by delivering ionizing radiations to the dilated area after the endovascular procedure. Experimental studies and multicenter clinical trials have reported the beneficial effects of endovascular beta or gamma ionizing radiation on vascular restenosis. Experimental studies in animals and recent clinical trials clearly show that external irradiation also reduces neointimal proliferation after arterial injury thus opening the way for the clinical assessment of ionizing radiations on arteries. In a previous experimental study, we reported that irradiation has a dose-dependent effect on the prevention of restenosis: a dose larger than 10 Gy is needed to obtain a significant reduction of intimal hyperplasia.

Objective: the main objective is to assess external ionizing radiation for restenosis prevention on prosthetic haemodialysis vascular accesses after angioplasty. A secondary objective is to assess the treatment safety.

Methods: Single blind randomized clinical trial on two parallel groups of 53 patients each. Patients with chronic renal failure treated by dialysis will be included after a successful angioplasty on a stenosis of the vein adjacent to their prosthetic haemodialysis vascular access. One group will be treated by a single dose of ionizing radiations (14 Gy) at day 1 after angioplasty. The control group will not receive any preventive treatment. The primary outcome is the one-year vascular access patency failure. Secondary outcomes are the one-year delay of occurrence of a restenosis and the treatment safety. Outcomes will be assessed by a clinical and ultrasonographic (at 1, 3, 6 and 12 months, or at other time points in case of stenosis suspicion) follow-up.

03

Conditions studied

  • Renal Insufficiency, Chronic
  • Graft Occlusion, Vascular
  • Thrombosis
  • Intimal Hyperplasia

Keywords

  • Randomized Controlled Trials
  • Renal Dialysis
  • Graft Occlusion, Vascular
  • Angioplasty
  • Vascular Patency
  • Radiation, Ionizing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • over 18 years
  • successful angioplasty (residual stenosis \< 30%) on a significant stenosis (maximal systolic speed 3 times > from basal maximal systolic speed, stenosis > 70% on angiography) on the venous-prosthesis anastomosis or on the venous segment 5 cm after the anastomosis of a prosthetic haemodialysis vascular access (at least 1 month old)
  • social security affiliation
  • signed

Exclusion criteria

Exclusion Criteria:

  • of radiotherapy
  • angioplasty with stenting
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Active comparator
    1

    14 Gy ionizing radiations

    Device: External ionizing radiations

  • No intervention
    2

Interventions

  • DeviceExternal ionizing radiations

    14 Gy in one time

06

What researchers measure

Primary outcomes

  1. Thrombosis or stenosis > to 70% or indication of a new treatment of stenosis during the 12 month follow-up

    Time frame: 1, 3, 6 and 12 month after initial angioplasty

Secondary outcomes

  1. Stenosis (> to 70%) or thrombosis or indication of a new treatment occurring

    Time frame: 1, 3, 6 or 12 months after initial angioplasty

  2. safety

    Time frame: 1, 3, 6 and months after initial angioplasty

07

Study locations

5 sites
  • Clinc Delay
    Bayonne, 64100, France
  • Côte Basque Hospital
    Bayonne, 64109, France
  • Service de Chirurgie Vasculaire, Hôpital Pellegrin-tripode, CHU de Bordeaux
    Bordeaux cedex, 33076, France
  • Clinic Saint Augustin
    Bordeaux, 33000, France
  • Clinic Francheville
    Perigueux, 24000, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2006
First posted
Sep 21, 2006
Start
Dec 2006
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Last update
Mar 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00379366
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Sep 21, 2006
Start date
Dec 2006
Primary completion
Jan 2009
Completion
Jan 2009
Last update
Mar 18, 2015

Study contacts

Jean-Philippe MAIRE, Pr
principal investigator · University Hospital, Bordeaux, France
Paul Perez, Dr
study chair · University Hospital, Bordeaux, France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion